Delta variant fueling new spike in cases across U S as 100 million Americans remain unvaccinated msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
This article was written by WTOP’s news partners at Maryland Matters and republished with permission. Sign up for Maryland Matters’ free email subscription today.
In a recently-produced video circulating on social media, Rep. Andrew P. Harris (R-Md.) urges people to get vaccinated against COVID-19.
Joined by nine other Republican physician-legislators, Harris tells viewers that the development of safe and effective vaccines provides the country “a clear path to the eradication of the pandemic.”
“The FDA did not skip any steps,” he adds.
Rep. Larry Bucshon (R-Ind.)
said getting vaccinated will bring an end to “the government’s restrictions on our freedoms.”
Johns Hopkins Bloomberg School of Public Health
The 1.9 trillion-dollar American Rescue Plan Act aims to change the course of the pandemic, build a bridge towards economic recovery, and invest in racial justice.
Join us for a special Public Health Week webcast to look beyond the numbers to examine the American Rescue Plan’s short- and long-term implications for public health practice and health equity with a focus on impacts on state and local public health agencies and Schools of Public Health. Leaders from the Johns Hopkins Center for Health Equity, Association of State and Territorial Health Officials, Association of Schools and Programs of Public Health, and the Big Cities Health Coalition will join in the discussion.
Why Biden Should Pick Sharfstein, Not Woodcock, to Run FDA
Joe Biden faces a crucial decision in deciding whether to go with FDA retread Janet Woodcock or the scholar and administrator Joshua Sharfstein.
While President Joe Biden has announced his decisions for the secretary of health and human services and for the director of the Centers for Disease Control and Prevention, he hasn’t announced a choice for the Food and Drug Administration (FDA). He appears to be wavering between two candidates longtime FDA drug regulator Janet Woodcock and former principal deputy commissioner Joshua Sharfstein, who is now at Johns Hopkins. Biden’s hesitation has created a battle royale among FDA veterans, public health experts, and pharmaceutical industry insiders over who is best suited to lead the agency through the coronavirus pandemic and to revive it. But there are multifarious reasons why the right nomination seems patently obvious. Woodcock is a creature of the FDA bureaucracy, while
To embed, copy and paste the code into your website or blog:
Medical device companies should be prepared for an increase in FDA enforcement activity with the incoming Biden administration, in addition to changes in agency leadership and repeals of regulatory reform.
As President-elect Joseph Biden gears up to take office on January 20, the upcoming change in administration will impact the US Food and Drug Administration’s (FDA’s) oversight and regulation of medical devices and digital health. The most immediate and significant changes impacting FDA’s medical device oversight are likely to include a repeal of certain Trump administration orders on regulatory reform and changes in leadership at both FDA and the US Department of Health and Human Services (HHS). Certain FDA priorities, however, including efforts to prioritize COVID-19-related medical devices and digital health technologies, are expected to continue under the new administration. Device companies should be prepared